Clinical Trial Update: A Phase I Trial of ZIO-101 in Hematologic Cancers [Phase 1]

View source ↗

Summary

This document reports the completion status of a Phase I trial evaluating ZIO-101 in hematologic cancers sponsored by Alaunos Therapeutics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Lymphoproliferative Disorders
• Multiple Myeloma
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms

Drugs mentioned

• ZIO-101

Snippet

Sponsor: Alaunos Therapeutics | Conditions: Acute Leukemia, Chronic Myeloproliferative Disease | Phase 1 | Status: COMPLETED